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Abstract
The Rac1 GTPase is an essential and ubiquitous protein that signals through numerous pathways 
to control critical cellular processes, including cell growth, morphology, and motility. Rac1 
deletion is embryonic lethal, and its dysregulation or mutation can promote cancer, arthritis, 
cardiovascular disease, and neurological disorders. Rac1 activity is highly regulated by 
modulatory proteins and posttranslational modifications. Whereas much attention has been 
devoted to guanine nucleotide exchange factors that act on Rac1 to promote GTP loading and 
Rac1 activation, cellular oxidants may also regulate Rac1 activation by promoting guanine 
nucleotide exchange. Herein, we show that Rac1 contains a redox-sensitive cysteine (Cys18) that 
can be selectively oxidized at physiological pH because of its lowered pKa. Consistent with these 
observations, we show that Rac1 is glutathiolated in primary chondrocytes. Oxidation of Cys18 by 
glutathione greatly perturbs Rac1 guanine nucleotide binding and promotes nucleotide exchange. 
As aspartate substitutions have been previously used to mimic cysteine oxidation, we 
characterized the biochemical properties of Rac1C18D. We also evaluated Rac1C18S as a redox-
insensitive variant and found that it retains structural and biochemical properties similar to those 
of Rac1WT but is resistant to thiol oxidation. In addition, Rac1C18D, but not Rac1C18S, shows 
greatly enhanced nucleotide exchange, similar to that observed for Rac1 oxidation by glutathione. 
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We employed Rac1C18D in cell-based studies to assess whether this fast-cycling variant, which 
mimics Rac1 oxidation by glutathione, affects Rac1 activity and function. Expression of Rac1C18D 
in Swiss 3T3 cells showed greatly enhanced GTP-bound Rac1 relative to Rac1WT and the redox-
insensitive Rac1C18S variant. Moreover, expression of Rac1C18D in HEK-293T cells greatly 
promoted lamellipodia formation. Our results suggest that Rac1 oxidation at Cys18 is a novel 
posttranslational modification that upregulates Rac1 activity.
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1. Introduction
Rac1 is a member of the Rho subclass of Ras superfamily GTPases. It functions as a 
molecular switch by cycling between active GTP- and inactive GDP-bound states to control 
the timing and specificity of cellular pathways that regulate diverse cell functions, including 
gene expression, cell motility, cell morphology, and cell cycling [1]. Owing to the slow 
intrinsic rates of nucleotide exchange and hydrolysis, temporal regulation of Rac1 activity 
requires modulatory factors, such as guanine nucleotide exchange factors (GEFs)2, which 
facilitate exchange of GDP for GTP; GTPase-activating proteins (GAPs), which catalyze 
GTP hydrolysis; and guanine nucleotide dissociation inhibitors (GDIs), which prevent GDP 
dissociation and sequester Rac1 away from cell membranes [2,3]. In addition, Rac1 is 
spatially and temporally regulated by various posttranslational modifications, including C-
terminal lipidation [4–6], phosphorylation [7], ubiquitination [8,9], and SUMOylation [10]. 
Rac1 is an essential protein [11] that plays a critical role in regulating multiple cellular 
processes. Its dysregulation is correlated with many diseases, including cancer [12,13], 
osteoarthritis [14], cardiovascular disease [15], and neurological disorders [16]. Until 
recently, upregulation of the activity of Rho family GTPases in cancer was believed to result 
solely from altered Rac1 expression levels and/or aberrant expression or regulation of Rac1 
GEFs, GAPs, and GDIs [17,18]. However, oncogenic mutations have been discovered in 
Rac1, Rac2, and Cdc42 [19]. In particular, a Rac1P29S mutant has recently been identified in 
9% of primary melanomas [20], which drives oncogenic transformation in melanocytes due 
to increased nucleotide cycling [21–23], and Rac2P29L has been sporadically observed in 
human melanoma and breast cancers [24]. Another mutant, Rac1N92I, was identified in the 
fibrosarcoma cell line HT1080 [24]. Further, the Rac1 splice variant Rac1b also promotes 
fast nucleotide cycling and has been shown to promote cellular transformation [25] as well 
as sustaining tumor survival [26]. Whereas most oncogenic mutations identified in Ras 
family proteins cause chronic activation by impairing GAP-mediated GTP hydrolysis [27], 
oncogenic mutations in Rho family GTPases promote increased guanine nucleotide 
exchange in a GEF-independent manner, which results in constitutive activation [19].
In addition to GEF-mediated regulation and mutation, reactive oxygen and nitrogen species 
(ROS and RNS) can directly facilitate guanine nucleotide exchange and Rac1 activation 
[28]. Although ROS and RNS are best known for their role in oxidative stress, in which they 
induce DNA damage as well as oxidize lipids and proteins [29], ROS and RNS have been 
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shown to regulate cellular signaling at physiological levels [30,31]. Cellular oxidants, such 
as nitrogen dioxide , superoxide , hydrogen peroxide (H2O2), and peroxynitrite 
(ONOO−), have been shown to specifically react with protein thiols and alter protein activity 
[32]. In fact, we have previously shown that oxidants, such as nitrogen dioxide, superoxide, 
and peroxide, can react directly with Rac1 Cys18 and regulate Rac1 activity by promoting 
guanine nucleotide exchange in vitro [28]. Moreover, Rac1 can be activated by exogenous 
addition of peroxide to HeLa cells [33].
Osteoarthritis is a degenerative joint disease that is characterized by high levels of oxidative 
stress [34], and increased Rac1 activity has been shown to regulate disease progression [14]. 
Rac1 activity has also been found to be elevated in human osteoarthritis cells [14,35]. 
Moreover, in primary chondrocytes, Rac1 activation increases the expression of matrix 
metalloproteinase 13 (MMP-13) [35], an enzyme known to play a role in cartilage matrix 
degradation. In both of these studies, ectopic expression of inactive Rac1 or use of a 
chemical inhibitor to Rac1 reduced the level of cartilage destruction and disease progression, 
indicating a direct role for Rac1 activity in osteoarthritis.
In addition to direct regulation of Rac1 activity by ROS and RNS, Rac1 associates with and 
can regulate enzymes that produce ROS and RNS. Rac1 binds to and activates NADPH 
oxidase (NOX) isoforms (Nox1, Nox2, and Nox3) [36,37]. Once activated, the NOX 
complex produces superoxide, a common cellular ROS. Superoxide has a short half-life and 
can be reduced by superoxide dismutase 1 (SOD1) to peroxide, a less reactive ROS [38]. 
Rac1 has also been shown to directly interact with SOD1 in a redox- and nucleotide-
dependent manner [39]. In a study by Harraz et al. [39], dithiothreitol (DTT)-reduced 
GTPγS-loaded Rac1 associated with SOD1, whereas exposure of GTPγS-bound Rac1 to 
peroxide at concentrations as low as 50 pM reduced association with SOD1 in vitro. These 
data suggest that oxidation of Rac1 can regulate its activity and alter interactions with 
regulatory proteins and effectors. Rac1 can also associate with and directly regulate the 
activity of endothelial and neuronal nitric oxide synthases (eNOS and nNOS) [40]. Nitric 
oxide (NO•) generated from NOS is involved in numerous physiological processes [41], 
including vascular function [42], neurotransmission [43], and pathogen defense [44]. As 
Rac1 can regulate both nitric oxide production from NOS enzymes and superoxide 
production from NOX complexes, Rac1 likely modulates peroxynitrite generation in cells. 
Peroxynitrite is a potent oxidant that can easily cross membranes and directly oxidize thiols 
and iron–sulfur centers in proteins via direct (nonradical-mediated oxidation) or indirect 
(radical-mediated oxidation) mechanisms [45].
Given that Rac1 colocalizes with and modulates the activity of several redox enzymes, 
including Nox1/2/3, SOD1, eNOS, and nNOS, we investigated the effects of oxidative 
modification on Rac1 activity in vitro and in cells. We found that Rac1 has a redox-sensitive 
cysteine in the phosphoryl-binding loop (p-loop) that can be selectively oxidized by 
glutathione in vitro, and Rac1 was observed to be glutathiolated in primary chondrocytes. 
Further, Rac1 Cys18 glutathiolation perturbs guanine nucleotide binding and promotes 
guanine nucleotide cycling. We prepared a Rac1C18D variant designed to place a negative 
charge in the nucleotide-binding pocket, similar to sulfinic/sulfonic acid oxidation and 
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glutathiolation, and found that the Rac1C18D variant shows greatly increased nucleotide 
dissociation rates in vitro, similar to glutathiolated Rac1 (Rac1S–SG). Further, the Rac1C18D 
variant shows increased activation in HEK-293T cells and enhances lamellipodia formation 
in Swiss 3T3 cells. We have also generated and char-acterized Rac1C18S, a redox-insensitive 
Rac1 variant that is resistant to glutathiolation. Taken together, our findings suggest that 
Rac1 oxidation may promote enhanced nucleotide cycling in a GEF-independent manner, 
which could lead to increased Rac1 cellular activation. Thus, given the role of Rac1 in 
regulating cellular oxidant production, dysregulation of Rac1 via oxidative posttranslational 
modifications may contribute to a variety of disease states in which the redox state is altered.
2. Materials and methods
2.1. Rac1 glutathiolation in primary chondrocytes
Human articular chondrocytes were isolated from normal articular cartilage obtained from 
tissue donors and cultured as previously described [35]. Confluent cultures were made 
serum-free overnight before treatment with 25 μM menadione for 0, 10, or 30 min to induce 
ROS production with or without 100 ng/ml insulin-like growth factor-1 (IGF-1) for 10 min. 
Cell lysates were prepared as previously described [35] with the addition of 20 mM 
iodoacetamide and 200 U/ml bovine liver catalase to the lysis buffer. Cell lysates with equal 
amounts of total protein were immunoprecipitated with antibodies to Rac1 (clone 23A8 
from EMD Millipore; Darmstadt, Germany) using the Pierce Classic IP Kit (Thermo 
Scientific; San Jose, CA, USA). Immunoprecipitated proteins were separated by SDS–
PAGE under nonreducing conditions and then immunoblotted with a mouse monoclonal 
antibody (Arbor Assays; Ann Arbor, MI, USA) to detect protein glutathiolation, which was 
followed by stripping the blot and reprobing for Rac1.
2.2. Expression and purification of recombinant proteins
Human Rac1WT (1–188, C178S) and the Rac1 Cys18 variants were cloned into pET15b 
(EMD Millipore), transformed into Escherichia coli BL21 (DE3) Rosetta2 cells (Stratagene; 
La Jolla, CA, USA), and grown at 37 °C to 0.6 OD600. Rac1 expression was induced upon 
adding 1 mM isopropyl-β-D-1-thiogalactopyrano-side. The cells were grown for 4 h at 37 °C 
before lysis in 50 mM KH2PO4 (pH 7.5), 150 mM NaCl, 1 mM MgCl2, 10 μM GDP, and 5 
mM β-mercaptoethanol (βME). All Rac1 and Rac1 Cys18 variants were purified using a Ni–
NTA column (Qiagen; Venlo, Limburg, The Netherlands) with a linear elution gradient 
from 0 to 300 mM imidazole. For longer term storage, purified Rac1 proteins were stored in 
50% glycerol at −20 °C. The RhoGAP domain (residues 244–431) was cloned into the 
pQlinkH vector (Addgene), and human Tiam1 (GEF domain containing the DH/PH domain, 
residues 1040–1397) was cloned into pET28a. Similar to Rac1 expression and purification, 
these constructs were transformed into E. coli BL21 (DE3) Rosetta2 cells. The cells were 
lysed in 20 mM Na2HPO4 (pH 7.4), 150 mM NaCl, 20 mM imidazole, and 5 mM βME and 
purified using Ni–NTA agarose affinity chromatography (Qiagen).
2.3. Rac1 glutathiolation
Oxidized glutathione (GSSG) was added to Rac1 at 1000-fold excess for 15–60 min at 25 or 
37 °C (time and temperature were varied to increase yield) in glutathiolation buffer (50 mM 
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KH2PO4 (pH 6.5), 150 mM NaCl, 5 mM MgCl2, 50 μM GDP, and 0.1 mM 
diethylenetriaminepentaacetic acid (DTPA)). The sample was dialyzed against prechilled 
buffer (20 mM KH2PO4 (pH 6.5), 50 mM NaCl, 5 mM MgCl2, 10 μM GDP, and 0.1 mM 
DTPA) overnight.
2.4. Mass spectrometry of unmodified Rac1, glutathiolated Rac1, and ABD-modified Rac1
Rac1 mass measurements were performed on an LTQ Orbitrap Velos mass spectrometer 
(Thermo Scientific). The mass analysis of intact Rac1 samples was achieved in full-MS, 
single-ion monitoring, and electron transfer dissociation–tandem mass spectrometry (ETD–
MS/MS) modes with a resolution of 120,000 at m/z 400 Da. The intact MS spectra were 
mass deconvoluted using ProMass, and ETD–MS/MS product ion spectra were processed 
manually by assigning sequence ions to theoretical masses corresponding to glutathiolated 
Rac1 or ABD-modified Rac1.
2.5. GDP dissociation assay
Rac1 was preloaded with 2′-/3′-O-(N′-methylanthraniloyl)guanosine-5′-O-diphosphate 
(mant-GDP; Biolog; Bremen, Germany) in 20 mM Tris (pH 7.5), 50 mM NaCl, 200 mM 
(NH4)2SO4, and 0.1 mM ethylenediaminetetraacetic acid (EDTA) for 1 h at 37 °C. The 
reaction was incubated on ice for at least 1 h upon adding 20 mM MgCl2. The excess 
nucleotide was removed, and Rac1 was buffer exchanged into 20 mM Tris (pH 7.5), 150 
mM NaCl, and 5 mM MgCl2. Nucleotide dissociation was initiated by addition of a 1000-
fold excess of unlabeled GDP, and the nucleotide dissociation rate was determined by 
monitoring the fluorescence emission at 435 nm (excitation 365 nm) using an LS50B 
spectrophotometer (PerkinElmer; Waltham, MA, USA). Where indicated, the minimal 
catalytic fragment of the Rac1 GEF Tiam1 containing the DH/PH domain was used to 
stimulate Rac1 nucleotide dissociation [46]. All dissociation experiments were performed in 
triplicate. The fluorescent nucleotide dissociation curves were fit to a one-phase exponential 
decay equation using GraphPad Prism 5.0.
2.6. GTP hydrolysis
Rac1 single-turnover GTP hydrolysis rates were determined in the presence and absence of 
the RhoGAP domain of p50 rhoGAP (1:1000 GAP:Rac1) essentially as described [47]. 
Inorganic phosphate was removed from all buffers using the “phosphate mop,” consisting of 
0.5 mM inosine in each of the following buffers and dialyzing the buffer in the presence of 1 
unit of nucleoside phosphorylase [48]. Rac1 was loaded with GTP by incubating with 10-
fold excess GTP at 37 °C for 1 min in 20 mM HEPES (pH 8), 20 mM (NH4)2SO4, 1 mM 
EDTA, and 0.1 mM DTPA. Excess GTP was removed using a PD-10 column (GE 
Healthcare). The reaction was performed in triplicate using a buffer containing 20 mM Tris 
(ph 7.4), 50 mM NaCl, 0.1 mM EDTA, and 0.5 mM inosine. GTP hydrolysis was initiated 
by adding 100 μM MgCl2 to a sample containing 50 μM Rac1 and FlipPi 5U (Addgene). 
FlipPi undergoes a conformational change upon binding inorganic phosphate, which alters 
its intrinsic fluorescence resonance energy transfer (FRET), as previously described [49]. 
Phosphate released from the hydrolysis of GTP to GDP was quantified to determine Rac1 
GTP hydrolysis rates by monitoring the FlipPi FRET signal change using a Spec-tramax 
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M5e spectrometer (excitation 415 nm and the emission ratio for 475 and 515 nm). The data 
were normalized and fit to a single association exponential (Prism 5.0; GraphPad; San 
Diego, CA, USA; n=2).
2.7. Rac1 Cys18 thiol pKa measurements
Rac1WT and Rac1C18S were dialyzed into reducing buffer (15 mM HEPES (pH 8.0), 50 mM 
NaCl, 5 mM MgCl2, 10 μM GDP, and 10 mM DTT), and the protein was incubated under 
reducing conditions for 30 min. Rac1 was then buffer exchanged using a Centricon 
concentrator (15-kDa molecular weight cut-off, Millipore) into nonreducing buffer (15 mM 
MES (pH 6.5), 30 mM NaCl, 5 mM MgCl2, 200 μM DTPA, and 10 μM GDP). Rac1 was 
diluted into a mixed buffer system with pH values ranging from 5.5 to 8.5; each buffer 
contained 30 mM MES, 30 mM MOPS, 30 mM Tricine, 5 mM MgCl2, 50 mM KCl, and 
200 μM DTPA. ABD-f (4-(aminosul-fonyl)-7-fluoro-2,1,3-benzoxadiazole; Anaspec; 
Fremont, CA, USA) was added (1 mM) to initiate cysteine thiol modification. The reaction 
rate was determined by monitoring ABD-f fluorescence (excitation 389 nm, emission 513 
nm) using a Spectromax M5e spectrometer (Molecular Devices; Sunnyvale, CA, USA). The 
initial reaction rates were fitted using linear regression analysis (Prism 5.0; GraphPad).
2.8. Rac1 circular dichroism and thermal stability
Circular dichroism data were collected on a JASCO J-815 CD spectrometer (Oklahoma 
City, OK, USA) with a JASCO Peltier device and water bath to control the temperature. 
Experiments were performed in a 1-mm cuvette at a protein concentration of 15 μM in 10 
mM potassium phosphate (pH 6.5). Far-UV scans were from 200 to 280 nm. Thermal 
denaturation of Rac1 and Rac1 variants were monitored at 222 nm to estimate the protein 
melting temperature. The temperature ramp rate was 1 °C/min and data points were 
collected every 1 °C. All data are reported in units of mean residue ellipticity, which was 
calculated as follows: [θ]MRE = (θraw × MRW)/(10 × c × l), where θraw is the ellipticity in 
degrees, MRW is (molecular mass in kilodaltons)/(No. of residues – 1), c is the protein 
concentration in g/ml, and l is the pathlength of the cuvette in cm, according to [50].
2.9. NMR experiments
Rac1 was expressed and purified as described above except that the cells were grown 
in 15N-enriched M-9 minimal medium. Two-dimensional (2D) 1H–15N HSQC 
(heteronuclear single-quantum coherence spectroscopy) NMR experiments were performed 
using a Varian Inova 700-MHz spectrometer with a cryoprobe. The sample contained 200 
μM Rac1, Rac1C18S, or Rac1C18A at 25 °C in 50 mM Tris maleate (pH 6.8), 50 mM NaCl, 5 
mM MgCl2, 50 μM GDP, 0.1 mM DTPA, and 1 mM DTT. The Rac1C18D variant was 
collected on a Bruker 700-MHz spectrometer (Billerica, MA, USA). Two-
dimensional 1H–15N HSQC NMR spectra were collected and recorded using a 2500-Hz 15N 
spectral width and 512 complex points. The NMR data were processed using NMR Pipe and 
NMRViewJ [51,52].
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2.10. Cell lines, plasmids, and reagents
HEK-293T cells (from the American Type Culture Collection) and Swiss 3T3 cells (a gift 
from Alan Hall, Memorial Sloan Kettering Cancer Center) were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (Sigma; St. 
Louis, MO, USA) and maintained at 37 °C in 5% CO2 [53]. Keith Burridge (University of 
North Carolina) provided full-length human Rac1 and the full-length Rac1C18S variant, 
which were cloned into the pCMVJ3 vector for mammalian expression; pCMVJ3-Rac1C18D 
was generated from Rac1WT using PCR-based mutagenesis.
2.11. PAK pull-down assays for Rac1-GTP in HEK-293T cells
Levels of active, GTP-bound Rac1 were assessed using pull-down assays with the PAK1 
p21-binding domain (GST-bound PAK-PBD, a gift from Keith Burridge) as described 
previously [54]. Briefly, HEK-293T cells were transiently transfected with Rac1 expression 
plasmids using the TransIT transfection reagent (Mirus; Madison, WI, USA) according to 
the manufacturer’s instructions. The next day or at 80–90% confluence, the cells were 
starved in serum-free DMEM for 3 h. Next, the cells were washed twice with ice-cold 
phosphate-buffered saline (PBS; 5.4 mM KCl, 1.7 mM KH2PO4, 13 mM NaCl, and 5.4 mM 
Na2HPO4 (pH 7.4)) and lysed in magnesium lysis buffer (50 mM Tris (pH 7.5), 10 mM 
MgCl2, 150 mM NaCl, 1% NP-40, 10% glycerol, and 0.25% Na deoxycholate) with 
protease inhibitors. Equal volumes were removed from each lysate for total protein analysis. 
Glutathione (GST) agarose beads containing 20 μg of GST–PAK-PBD were added to each 
lysate and incubated at 4 °C for 60 min. Agarose–GST–PAK-PBD and associated Rac1 
were pelleted and washed three times with 500 μl of wash buffer (25 mM Tris (pH 7.5), 40 
mM NaCl, and 30 mM MgCl2). The final pellets were suspended in 1× protein sample 
buffer and resolved using SDS–PAGE. Rac1 protein and variants were detected through 
immunoblotting using an anti-Rac antibody (Millipore). Equal protein loading was 
confirmed using anti-tubulin (Sigma–Aldrich), and the Rac1C18S and Rac1C18D data were 
normalized to the Rac1WT data.
2.12. Cytoskeleton assays in Swiss 3T3 cells
Swiss 3T3 cells were plated (5000 cells/well in 12-well plates) on coverslips previously 
coated with fibronectin (2.5 μg/ml) for 30 min at room temperature. The next day, Myc-
tagged Rac1 constructs were transiently transfected into the cells using TransIT (Mirus) 
according to the manufacturer’s instructions. Twenty-four hours after transfection, the cells 
were fixed and stained with phalloidin and for the Myc-tag, as previously described [55]. 
Briefly, the cells were fixed in 4% paraformaldehyde (Electron Microscopy Sciences; 
Hatfield, PA, USA) overnight at 4 °C, permeabilized in 0.2% Triton X-100 (Sigma) in PBS 
for 5 min, and incubated with anti-Myc 911B antibody (1:500, Cell Signaling) for 1 h, 
followed by secondary AlexaFluor 488 anti-mouse antibody (1:500, Invitrogen) for 2 h and 
AlexaFluor 568 phalloidin (Invitrogen, 1:40 in PBS) for 30 min. The cells were incubated in 
the dark and rinsed in PBS three to five times between each step. Coverslips were mounted 
using 6 μl Vectashield with DAPI (Vector Laboratories; Burlingame, CA, USA). Cells were 
visualized and counted blindly for lamellipodia using a Nikon Eclipse TS100 microscope 
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with a 40× objective. Representative images were recorded using a Zeiss LSM 710 confocal 
laser-scanning microscope with a 63× oil objective.
3. Results
We have previously shown that Rac1 activity can be directly modulated by ROS and RNS 
[28]. Our earlier studies focused on radical-mediated regulation of Rac1 activity, in which 
we found that oxidants (  and ) capable of generating a Cys18 thiyl radical caused 
guanine base oxidation and nucleotide dissociation in Rac1; however, we also observed that 
peroxide, a nonradical oxidant, increased the intrinsic rate of exchange by ~10-fold [28]. As 
S-glutathiolation is commonly observed after thiyl radical formation because of the high 
cellular glutathione concentration [56], we expanded on these studies by examining whether 
glutathione modification can alter Rac1 activity. Given that Rac1 Cys18 is located in the 
nucleotide-binding pocket and forms multiple interactions with the guanine nucleotide 
ligand, we postulated that Cys18 is redox-sensitive, and oxidation of this thiol could alter 
guanine nucleotide binding and the Rac1 activation state.
3.1. Rac1 is glutathiolated in primary chondrocytes and is specifically glutathiolated at 
Cys18 in vitro
Rac1 has previously been shown to contribute to the development of osteoarthritis, probably 
because of its ability to upregulate MMP-13 expression in articular chondrocytes [14,35]. 
Therefore, we used primary human chondrocytes to examine whether endogenous Rac1 is 
glutathiolated. The cells were treated with menadione, which induces ROS production, in 
the absence and presence of the growth factor IGF-1, to examine the effects of ROS on IGF 
signaling. As shown in Fig. 1, menadione treatment, but not IGF-1, increased the level of 
Rac1 glutathiolation. Detection of glutathiolated Rac1 was greatest at 10 min after 
menadione addition and declined at 30 min.
Given that Rac1 Cys18 is solvent accessible (Supplementary Table 1) and sensitive to ROS 
and RNS [28], we explored whether Cys18 in Rac1 can be specifically glutathiolated in 
vitro. To generate glutathiolated Rac1 (Rac1S–SG), Rac1WT was treated with 1000× GSSG. 
The reaction products were analyzed by MS. Fig. 2 shows the intact mass analysis of 
Rac1WT treated with GSSG at pH 6 and 7.5, as well as the subsequent characterization of 
Rac1 with a single glutathione modification by top-down mass spectrometry. We were able 
to semi-quantitatively assess the amount of adduct formed by comparing the normalized 
peak intensity of unmodified Rac1 to the intensity of the Rac1 glutathiolated peak. These 
analyses also show that the amount of glutathiolated Rac1 is dependent on the pH of the 
reaction. Fig. 2A shows the deconvoluted MS of Rac1 treated with GSSG at pH 7.5 that 
resulted in ~25% glutathione adduct (normalized to base peak of Rac1), and Fig. 2B shows 
the deconvoluted MS of Rac1 treated with GSSG at pH 6 that resulted in ~10% glutathione 
adduct (normalized to base peak of Rac1). The twofold drop in glutathiolation observed in 
the MS data of intact Rac1 suggests that a single cysteine residue in Rac1 is modified in a 
pH-dependent manner. These observations are consistent with data in Supplementary Fig. 1, 
in which ESI–MS performed on Rac1WT and Rac1C18S show glutathiolation for Rac1WT but 
not Rac1C18S, indicating that Cys18 is the primary site of glutathiolation in Rac1.
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The site of Rac1 glutathiolation was characterized by top-down mass spectrometry by 
subjecting the [M+16H+G]16+ ion (Z=16+ of Rac1 containing a single glutathione) to ETD. 
The resulting MS/MS product ion spectrum consists of the major c- and •z-type fragment 
ions, shown at two different mass ranges for clarity. Data in Fig. 2C show products spanning 
m/z 800–1500 Da, and Fig. 2D shows all product ions spanning m/z 1500–2000 Da. The 
lower m/z region resulted in mostly singly charged c- and •z-type product ions from C-
terminal residues, whereas the N-terminal fragment ion c45+G contained the only 
glutathione-containing product ion. Most of the N-terminus lacked structurally informative 
fragments because of the lower number of basic amino acid residues. In addition, the neutral 
loss of glutathione during ETD was occasionally observed. Conversely, the higher m/z 
region produced structurally rich c-type ions, i.e., c87+G, and a number of other larger 
multiply charged c-type ions that contained glutathione (Fig. 2E). Our ability to detect 
glutathiolated Rac1 fragments was probably due to preservation of the covalently attached 
disulfide bond of glutathione upon competitive fragmentation along the N–Cα backbone. 
These ions, along with complementary multiply charged •z-type fragment ions lacking 
glutathione (•z154, •z145, •z99), lead to unambiguous localization of glutathiolation to either 
Cys6 or Cys18. In further support of site-specific glutathiolation at Cys18, a Rac1 variant that 
lacks a cysteine at position 18 (Rac1C18S), but shows biochemical properties similar to 
Rac1WT, is not covalently modified by glutathiolation (Supplementary Fig. 1). Taken 
together, our data indicate that treatment of Rac1WT with GSSG results in specific 
glutathiolation of Rac1 Cys18.
3.2. Rac1 Cys18 glutathiolation perturbs guanine nucleotide binding and enhances the 
intrinsic GDP dissociation rate
As Cys18 is located in the p-loop of Rac1 and directly interacts with the bound guanine 
nucleotide, we hypothesized that glutathiolation at this site may interfere with nucleotide 
binding. To determine whether Rac1 glutathiolation alters guanine nucleotide dissociation, 
Rac1S–SG was preloaded with fluorescent GDP (mant-GDP), and the rate of GDP 
dissociation was determined. As shown in Fig. 3, oxidative modification of Rac1 Cys18 with 
glutathione enhances the rate of GDP dissociation by 200-fold. Adding the GEF domain 
(DH/PH) of Tiam1 to Rac1S–SG did not increase the GDP dissociation rate. However, as the 
intrinsic rate of GDP dissociation is rapid under our experimental conditions, it is unclear 
whether we have the dynamic range to detect GEF-mediated enhancement.
To better understand the enhanced nucleotide exchange properties associated with 
glutathiolated Rac1, we generated Rac1 C18D, C18S, and C18A variants. The Rac1C18D 
variant was generated because a Cys→Asp substitution has previously been shown to mimic 
a cysteine-to-sulfenic/sulfinic acid modification in recoverin [57]. As both Rac1C18D and 
Rac1S–SG introduce a negative charge into the phosphoryl-binding pocket, we also made 
more conservative Cys18 substitutions, including Rac1C18S and Rac1C18A. All variants were 
preloaded with fluorescent GDP (mant-GDP), and Rac1 GDP dissociation was determined 
by measuring the decrease in mant-GDP fluorescence as a function of time (Fig. 3A). The 
GDP dissociation rates of Rac1 and the Cys18 variants were also measured in the presence 
of the GEF domain of Tiam1. Similar to glutathiolated Rac1, Rac1C18D shows a greatly 
enhanced intrinsic rate of nucleotide dissociation that was approximately 200-fold faster 
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than that of Rac1WT and was not further increased by addition of Tiam 1. In contrast, 
Rac1C18S shows a similar GDP dissociation rate compared to Rac1WT, and Rac1WT and 
Rac1C18S were similarly responsive to GEF-mediated GDP dissociation. Consistent with 
previous studies of Cdc42C18A [58], the Rac1C18A variant enhances the intrinsic rate of 
GDP dissociation by 11-fold. These results indicate that the Cys18 thiol side chain plays a 
role in stabilizing nucleotide binding (Fig. 3B and Table 1).
In-cell regulation of Rac1 activity requires exchange of GDP for GTP to activate Rac1 and 
GTP hydrolysis for inactivation. To characterize the effects of Rac1 Cys18 variants on 
intrinsic and GAP-mediated GTP hydrolysis, we determined the rates of GTP hydrolysis of 
Rac1WT, Rac1C18D, and Rac1C18S in the presence and absence of the minimal catalytic 
domain of p50 rhoGAP. Single-turnover GTP hydrolysis rates were determined by 
monitoring phosphate release upon GTP hydrolysis by detecting the FRET change 
associated with the phosphate-binding protein FlipPi 5U. As shown in Fig. 3C and 
quantified in Table 2, mutating Rac1 Cys18 to either Asp or Ser did not significantly affect 
either the intrinsic or the GAP-mediated GTP hydrolysis rates. These data indicate that 
perturbation of Rac1 Cys18 by mutation, including the oxidation mimetic, does not alter 
GAP-mediated down regulation in vitro.
3.3. The Rac1 Cys18 thiol has a depressed pKa and can be selectively modified by ABD-f at 
physiological pH
As Rac1 Cys18 can be selectively modified by oxidized glutathione at physiological pH, we 
investigated whether the pKa of the Rac1 Cys18 thiol is altered relative to a typical free 
cysteine thiol by measuring the cysteine reactivity of Rac1WT and Rac1C18S to ABD-f. We 
used the thiol-modifying reagent ABD-f, which preferentially reacts with the thiolate form 
of cysteine [59], to measure thiol reactivity over a wide pH range, as described previously 
by us for Ras [60]. ABD-f fluorescence was measured from pH 5.5 to 8.5 for Rac1WT and 
Rac1C18S (Fig. 4A). The rate of ABD-f reactivity for Rac1WT was normalized to produce a 
pH titration curve for Rac1 Cys18 (Fig. 4B) and resulted in a pKa for the Rac1 Cys18 thiol of 
~7.25, which is approximately 1.5 pH units lower than a typical pKa for a free cysteine [61]. 
No significant reactivity was detected for Rac1C18S.
The Rac1 construct (Rac1 1–188, C178S) contains five cysteines, some of which are 
partially solvent accessible (Supplementary Table 1). Fig. 5 shows the intact mass analysis 
of Rac1WT and Rac1C18S that were reacted with ABD-f under the conditions used for 
glutathione modification. A single ABD-f modification site was identified by top-down 
mass spectrometry. The deconvoluted mass spectra of Rac1WT shown in Fig. 5A consists of 
major peaks corresponding to unmodified intact Rac1, Rac1 with a single ABD adduct mass, 
and Rac1 with a single deoxygenated adduct mass. Conversely, the deconvoluted mass 
spectra of the Rac1C18S variant, in Fig. 5B, show peaks corresponding to unmodified intact 
Rac1C18S, Rac1C18S with a sodium adduct, and two unidentified peaks ([M+76] and [M
+99]). However, an ABD adduct is not observed for Rac1C18S, suggesting that the Rac1WT 
ABD adduct occurs exclusively at Cys18. This result is consistent with Rac1WT 
glutathiolation MS data (Fig. 2) in which a single glutathione adduct was observed at Cys18. 
The ESI–MS spectra for Figs. 5A and 5B are shown in Supplementary Figs. 2A and 2B, 
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respectively. The site of the ABD adduct was further characterized by top-down mass 
spectrometry. Both [M+18H+ABD]18+ (Z = 18+ of Rac1 containing a single ABD) and [M 
+ 18H]18+ (Z = 18+ of unmodified Rac1) were subjected to ETD to comprehensively assign 
peaks modified by ABD-f. Fig. 5C shows the ABD-modified Rac1 sequence map annotated 
with observed major c- and •z-type fragment ions. The c27+ABD, c54+ABD −H2O, 
c123+ABD, c132+ABD, and c133+ABD ions as well as the z148 ion allow localization of the 
ABD adduct to either Cys18 or Cys6. The absence of the ABD adduct for the Rac1C18S 
variant confirms that Cys18 is the most likely site of ABD-f modification.
Supplementary Figure 3 shows the resulting ETD-MS/MS product ion spectra of Rac1 and 
Rac1+ABD as a tiled view to compare the fragmentation of unmodified and ABD-modified 
Rac1. Comparative analysis of peaks associated with top and bottom spectra show 
differences (difference spectral peaks) that assist in narrowing down the fragments 
containing ABD-f modification. The distinct product ion peaks along with all other observed 
product ions were used for the annotation of the sequence map shown in Fig. 5C. The major 
c- and •z-type fragment ions are shown at several different mass ranges for clarity.
Taken together, our data show that Cys18 is the only cysteine that appreciably reacts with 
ABD-f or GSSG at physiological pH values. These results indicate that Rac1 Cys18 has a 
depressed pKa, which populates the more reactive thiolate state under physiological 
conditions.
3.4. Thermal stability and structural analysis
As a decrease in nucleotide binding affinity is correlated with a decrease in stability for the 
Ras GTPase [62], we used CD to determine the total secondary structure content and 
thermal stability of Rac1, Rac1S–SG, and Rac1 variants. By comparing the overall secondary 
structure and thermal stability, we can evaluate whether Rac1S–SG and the Rac1 Cys18 
variant disrupts the overall protein fold. As shown in Fig. 6, the overall secondary structure 
content determined by CD spectroscopy was unchanged for Rac1S–SG. In contrast, the 
thermal stability was decreased by 9 °C relative to Rac1WT. As the nucleotide exchange rate 
was significantly increased in Rac1S–SG relative to Rac1WT, the change in Tm is probably a 
reflection of decreased nucleotide binding affinity. We also find that the secondary structure 
content and thermal stability of Rac1C18D are similar to those of Rac1S–SG. In contrast to 
mutations and oxidative modifications that promote fast cycling, the thermal denaturation of 
the redox-insensitive Rac1C18S variant was slightly higher than that of Rac1WT, with a Tm of 
69 °C compared to 67 °C for Rac1WT.
To determine how mutations at Cys18 perturb Rac1 in a site-specific manner, we employed 
NMR on 15N-enriched Rac1-GDP. We performed a 2D 1H–15N HSQC on Rac1WT, 
Rac1C18D, and Rac1C18S and compared the variants to the HSQC spectrum of Rac1WT, 
which has been previously assigned [63]. As we are able to detect one peak for every 
backbone amide with the exception of proline, this technique allows us to probe whether 
mutation at Cys18 causes localized or more global structural perturbations in Rac1. The 
2D 1H–15N HSQC overlay of Rac1WT and Rac1C18D is shown in Fig. 7A, with residues 
showing chemical shift changes mapped onto the Rac1 structure (pdb 1MH1) (Fig. 7B). 
Comparison of the NMR spectra of Rac1C18D and Rac1WT showed chemical shift 
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differences (22) in a small percentage (14%) of the total amides (chemical shifts greater than 
one line width). In addition, two amide peaks showed changes in linewidth. As shown in 
Fig. 7B, residues that undergo chemical shift changes upon mutation of Cys18 to Asp are 
highlighted in purple and are primarily localized to the p-loop, switch I, and SAx motif of 
Rac1 (switch II was not detected in the Rac1WT NMR spectrum).
In contrast, only nine residues show chemical shift changes for Rac1C18S compared to 
Rac1WT. Moreover, the residues displaying chemical shift changes correspond to residues 
proximal to the site of mutation (Fig. 7C). In Fig. 7D, a ribbon diagram of the structure of 
Rac1 (pdb 1MH1) is presented with residues showing chemical shift perturbations 
highlighted. Most of the residues that show peak changes are near the site of mutation, 
indicating that mutation of Cys18 to Ser does not significantly perturb the structure of Rac1, 
consistent with our findings that the biochemical properties and secondary structure of 
Rac1C18S are not significantly altered compared to Rac1WT. Further, these data support the 
use of Rac1C18S as a redox-insensitive variant of Rac1.
3.5. Rac1C18D is hyperactivated in HEK-293T cells
Our data indicate that both the Rac1C18D variant and glutathiolated Rac1 show greatly 
enhanced rates of GDP dissociation, similar to the Rac1 fast-cycling mutant (P29S) that 
promotes Rac1-mediated oncogenesis. The Rac1P29S mutant has a significantly faster 
nucleotide exchange rate and induces an activated phenotype in COS-7 cells [21]. As 
Rac1C18D shows greatly enhanced nucleotide dissociation (>200-fold), we postulated that 
this oxidative mimetic will populate Rac1 in the active, GTP-bound state in cells. Therefore, 
we examined the activation state of Rac1WT, Rac1C18D, and Rac1C18S in HEK-293T cells 
using a PAK1 pull-down assay. As shown in Fig. 8, Rac1WT and Rac1C18S show similar 
levels of association with PAK1-PBD. In contrast, Rac1C18D showed a 5-fold higher level of 
activation compared to Rac1WT and Rac1C18S, which is consistent with our observation that 
Rac1C18D has a greatly enhanced in vitro nucleotide dissociation rate compared with 
Rac1WT. As enhanced Rac1 activation has been previously observed in HeLa cells upon 
H2O2 addition [33], our data further support the hypothesis that oxidation at Rac1 Cys18 can 
modulate the Rac1 activation state.
3.6. Rac1C18D enhances Rac1-mediated lamellipodia formation in Swiss 3T3 cells
As we determined through PAK1 pull-down assays that Rac1C18D is more populated in its 
GTP-bound state compared with Rac1WT or Rac1C18S (Fig. 8), we sought to determine if the 
increased activity of Rac1C18D could induce a biological phenotype that indicates enhanced 
Rac1 signaling. A canonical function of active Rac1 is actin cytoskeleton changes that 
induce lamellipodia formation [64,65]. Therefore, we visualized the actin cytoskeleton 
through phalloidin staining in Swiss 3T3 cells expressing Rac1WT, Rac1C18D, or Rac1C18S. 
Cells expressing the Myc-tagged Rac1 constructs were identified by immunofluorescence, 
and lamellipodia formation in the Rac1-expressing cells was quantified. We determined that 
Rac1C18D expression increased lamellipodia formation 5- to 10-fold compared with Rac1WT 
and Rac1C18S (Fig. 9). Therefore, Rac1C18D can function similar to activated Rac1WT and 
promote lamellipodia formation.
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Among its many vital functions, the small GTPase Rac1 plays a key role in regulating redox 
enzymes, such as NOS and NOX, which generate nitric oxide and superoxide, respectively 
[66]. Moreover, Rac1 has been shown to interact directly with the antioxidant enzyme SOD1 
in a redox- and nucleotide-dependent manner [39]. Rac1 has also been shown to be directly 
regulated by ROS and RNS oxidants in vitro [28] and by exposure to peroxide in REF52 and 
HeLa cells [33]. These findings suggest that ROS and RNS regulate both Rac1-mediated 
oxidant production and Rac1 signaling.
Redox regulation by modification of cysteine residues has been shown to regulate the 
function of diverse types of signaling proteins. For example, the transcription factor NF-κB, 
which is a key mediator of Rac1 function, is one prominent example of a cell signaling 
protein that is regulated in part by cysteine oxidation [67,68]. NF-κB can be regulated 
directly by S-glutathiolation of its own p50 and/or p65 subunit or indirectly by S-
glutathiolation of its regulators IKK and IκBα [69]. In addition, p38 MAPK can be activated 
by reversible cysteine oxidation [70], whereas a number of protein tyrosine phosphatases 
become inactivated by oxidation of a catalytic cysteine [71]. In addition to these signaling 
proteins, we have previously reported that thiyl radical formation at Cys118 of the small 
GTPase Ras can regulate its activity [72,73]. This mechanism of activation appears to play a 
key role in Ras-mediated tumorigenesis [74]. However, we have previously shown that non-
radical-mediated cysteine oxidation (i.e., nitrosation and glutathiolation) of this solvent-
accessible cysteine does not alter Ras activity [75,76]. In contrast to Ras, the redox-sensitive 
cysteine in Rac1 (Cys18) has direct interactions with the bound nucleotide [77], and 
oxidation of this cysteine by both radical- and nonradical cysteine oxidation can impair 
guanine nucleotide binding, resulting in accelerated nucleotide exchange [28] and 
upregulation of Rac1 activity [33]. Given that cellular Rac1 colocalizes with enzymes that 
generate both ROS and RNS, Rac1 probably reacts with a variety of oxidants in the cell. 
Here, we show that cellular Rac1 is S-glutathiolated in chondrocytes. This oxidative 
modification leads to enhanced nucleotide exchange in vitro, which is a key step to promote 
Rac1 activation in cells. Consistent with these observations, we find that a Rac1 oxidative 
mimetic shows enhanced GTP-dependent effector binding and downstream sig-naling to the 
cytoskeleton.
The 305-Da S-glutathione modification is a common thiol oxidation product found under 
both basal conditions and oxidative stress [56,78] and has been observed in many proteins 
with redox-sensitive cysteine residues [69,79,80]. For example, the Ras GTPase undergoes 
S-glutathiolation at Cys118 upon exposure to peroxynitrite and DEA NONOate (an NO• -
donating agent) in bovine aortic endothelial cells [80,81]. We now show that Rac1 is S-
glutathiolated in primary chondrocytes upon menadione-induced ROS formation. 
Osteoarthritis is a degenerative joint disease that is characterized by high levels of oxidative 
stress in chondrocytes [34], and Rac1 activity is enhanced in osteoarthritic chondrocytes 
compared to normal cells [35]. Moreover, inhibition of Rac1 blocked production of the 
degra-dative matrix metalloprotease MMP-13 in chondrocytes [35] and reduced the severity 
of arthritis in a mouse model [14]. As we show here that S-glutathiolation of in vitro-
purified Rac1 Cys18 greatly accelerates nucleotide dissociation, a key mechanism of 
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activating Rac1, we postulate that Rac1 oxidation may promote its activation in degenerative 
joint disease and may play a role in driving arthritis progression.
In addition to S-glutathiolation, oxidation of cellular thiols by ROS can also promote the 
formation of sulfenic, sulfinic, and sulfonic acids. However, generation of a single species of 
oxidized thiol in vitro can prove difficult if not impossible. Previously, Permyakov et al. 
[57] used a Cys→Asp variant to mimic thiol oxidation in recoverin because aspartic acid 
shows similarity in shape and charge to sulfinic acid (Supplementary Fig. 4). As oxidation 
by ROS can yield several different oxidation products [32], use of the oxidation mimetic 
Rac1C18D allows for the study of a singly oxidized species. This variant shows greatly 
enhanced guanine nucleotide exchange, similar to glutathiolated Rac1, supporting the use of 
this variant as an oxidation mimetic. We also generated redox-insensitive Rac1C18S and 
Rac1C18A variants. Interestingly, we observe a trend toward increased nucleotide 
dissociation for Rac1C18S<Rac1C18A<Rac1C18D. Whereas the Rac1C18D variant has a 
dramatically enhanced (200-fold) GDP dissociation rate, similar to that observed for Rac1 
glutathiolation, the Rac1C18A variant possesses an approximately 11-fold increased rate of 
nucleotide exchange relative to Rac1WT. In contrast, the Rac1C18S variant has an intrinsic 
dissociation rate that is similar to that of Rac1WT. Therefore, the effect of mutation at Cys18 
on guanine nucleotide binding is dependent on the mutation type, with the less conservative 
negatively charged substitution (Rac1C18D) producing the largest perturbation in guanine 
nucleotide binding. Given these observations, we postulate that different oxidation states 
alter Rac1 activity in distinct ways.
Rac1 is well known as an inducer of cytoskeletal reorganization, such as membrane ruffling 
and lamellipodia formation [64,82]. Consistent with our in vitro data demonstrating 
increased nucleotide exchange, we observed that Rac1C18D is hyperactivated in HEK-293T 
cells and promotes lamellipodia formation in Swiss 3T3 cells, whereas Rac1C18S showed 
levels of cellular activation similar to those of Rac1WT. To the extent that the Rac1C18D 
variant mimics oxidized Rac1 (e.g., Rac1S–SG), these results suggest that oxidation of Rac1 
at Cys18 can promote Rac1 activation through increased nucleotide exchange. Furthermore, 
our results indicate that Rac1C18D retains the ability to bind to at least a subset of effector 
proteins that promote Rac1-mediated cytoskeletal changes. Thus, unlike other dynamic 
posttranslational modifications of Rac1, such as phosphorylation [83,84] and palmitoylation 
of the C-terminal membrane-targeting domain [6], which decrease Rac1 activity and/or alter 
Rac1 effector binding by altering its localization [85], oxidation of the N-terminal Cys18 
primarily enhances the population of activated Rac1.
Rac1 is also well known as an inducer of ROS and RNS [86]. However, in contrast to the 
enhancing effects of oxidation on Rac1-mediated cytoskeletal organization, cysteine 
oxidation of Rac1 has been reported to decrease its association with SOD1 [39]. Therefore, 
it will be interesting to determine whether its interactions with other redox enzymes, such as 
NOX [36,37] and NOS [40], are also negatively affected by Rac1 cysteine oxidation. If so, 
this could indicate the presence of a negative feedback loop that would further add to the 
complexity of Rac1-mediated redox signaling. Conversely, a positive feedback loop could 
exist in which oxidation of Rac1 may facilitate interactions with other effectors. Future 
studies will investigate whether Rac1 oxidation alters effector interactions.
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Finally, it is intriguing to note that Rac1 and Ras are differentially regulated by thiol 
oxidants. We have previously reported that thiyl radical formation at Ras Cys118 can 
promote guanine nucleotide exchange and Ras activation [72,73], whereas non-radical-
mediated nitrosation and glutathiolation does not alter Ras nucleotide binding [75,76]. In 
contrast, we show herein that Rac1 can be activated by nonradical oxidation at Cys18. We 
propose that the distinct locations of the redox-sensitive cysteines within the nucleotide 
binding motifs of Rac1 and Ras explain this differential regulation. We therefore performed 
sequence and structural analyses of the redox-sensitive motifs in the context of the redox-
sensitive thiols. Fig. 10A and 10B depict the redox-sensitive motifs contained within the 
protein structures ([77] and pdb 3GFT) for Rac1 and Ras, respectively. The redox-sensitive 
thiol in Rac1, Cys18, is within the GxxxxGK [S/T] motif, otherwise known as the p-loop, 
which places the thiol within hydrogen-bonding distance from the α-phosphate. However, in 
Ras, the redox-sensitive thiol lies within the [N/T] KxD motif and does not have direct 
interactions with other residues in Ras or with the bound nucleotide. Further, the thiol is 
located 6.6 Å away from the bound nucleotide and is solvent exposed. This difference in 
location can explain their distinct modes of regulation. For both Rac1 and Ras, thiyl radical 
formation at their respective cysteines can lead to oxidation of the bound nucleotide 
[28,72,73], which promotes nucleotide dissociation and can result in activation. We find by 
several complementary methods that thiol oxidation by nonradical oxidative mechanisms 
perturbs nucleotide binding only in Rac1 and not Ras ([75,76] and this study). Further, the 
altered pKa of Rac1 Cys18 (this study) relative to Ras [61] renders Rac1 susceptible to thiol 
oxidation at physiological pH. Hence, Rac1 Cys18 is susceptible to a wider array of 
oxidative modifications, including both radical and nonradical oxidation. This differential 
oxidant-mediated regulation is depicted in Fig. 10C and 10D.
5. Conclusions
In summary, our in vitro and cell-based experiments suggest that oxidative modification of 
Rac1 can increase Rac1 activity and downstream signaling by enhancing nucleotide 
exchange. In addition, our findings indicate that Rac1C18D may prove useful as an oxidation 
mimetic, whereas Rac1C18S is a redox-insensitive variant that displays biochemical 
properties, structure, and interactions with Rac1 regulators similar to Rac1WT under 
nonstressed conditions. Thus, the Rac1C18S variant should serve as a valuable tool to 
determine whether cellular oxidants act directly or indirectly on Rac1 and will aid in 
elucidating the role of Rac1 oxidation in normal and disease states. Our data support a 
potential new layer of regulation for Rac1 activation through oxidative modification. Redox 
regulation of Rac1 may not only directly modulate Rac1 activity but also provide a feedback 
mechanism for regulating major ROS- and RNS-modulating enzymes, including NOS, 
NOX, and SOD1, that are, in turn, regulated by Rac1. Our observations are particularly 
interesting given that Rac1 plays a critical role in cellular redox regulation and that both 
Rac1 and ROS/RNS are involved in multiple common pathophysiological conditions. For 
example, our finding that Rac1 is S-glutathiolated in primary chondrocytes suggests a 
possible mechanism for regulating Rac1 activity levels in osteoarthritis. It will be interesting 
to determine the role of Rac1 oxidation in this and other diseases, such as cancer, in which 
high levels of oxidative stress are present.
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eNOS endothelial nitric oxide synthase
ETD–MS/MS electron transfer dissociation–tandem mass spectrometry
FRET fluorescence resonance energy transfer
GAP GTPase-activating protein
GDI guanine nucleotide dissociation inhibitor
GEF guanine nucleotide exchange factor
GSSG oxidized glutathione
HSQC heteronuclear single-quantum coherence spectroscopy
IκBα nuclear factor of κ light polypeptide gene enhancer in B cells inhibitor, α
IKK IκB kinase
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RNS reactive nitrogen species
ROS reactive oxygen species
SOD1 superoxide dismutase 1
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Rac1 glutathiolation in human chondrocytes. Primary human chondrocytes were treated for 
10 or 30 min with 25 μM menadione to induce oxidative stress in the absence and presence 
of 100 ng/ml IGF-1. Cell lysates immunoprecipitated with a monoclonal antibody to Rac1 
were run on a nonreducing gel and immunoblotted with a monoclonal antibody to 
glutathione. The blot was stripped and reprobed with the Rac1 antibody.
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Mass spectrometry characterization of Rac1WT glutathione adducts. (A and B) Mass 
deconvoluted zero-charge spectra of the ESI full-MS spectra (Supplementary Fig. 1) 
associated with intact Rac1 treated with 1000× glutathione at pH 6 and 7.5, respectively. 
Note: A single glutathione adduct is seen at pH 6.0 and 7.5, with more adducts observed at 
higher pH. (C and D) Top-down product ion MS/MS spectra resulting from the ETD of [M
+16H+G]16+ (glutathiolated Rac1, Z = 16+, m/z = 1259.6 Da) with fluoranthene anions. 
Note: c- and z-type ions, nondissociated precursors (electron transfer with no dissociation), 
and precursors with fluoranthene (m/z = 202 Da) adducts (+F) of Rac1 were observed. As 
glutathione is prone to cleavage at the disulfide bond during ETD, some neutral loss 
glutathione ions were detected. In addition, z-type ions are prone to radical-mediated oxide 
adduction in ETD, which were detected. (E) ETD sequence ions mapped to Rac1 with 
putative glutathione sites highlighted by asterisks. Confident assignment of c- and z-type 
ions z154, z145, z99, and c45+G leads to the localization of the glutathione adduct to either 
Cys6 or Cys18 of Rac1.
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Oxidation of Rac1 Cys18 and Rac1 Cys18 variants alters guanine nucleotide exchange but 
not GTP hydrolysis. (A) Intrinsic mant-GDP dissociation curves for Rac1WT, Rac1C18S, 
Rac1C18D, and Rac1S–SG. The data were fit to a single exponential and standard errors were 
determined using Prism 5.0 (n = 3). (B) Bar graph of rates of intrinsic nucleotide exchange 
with GEF-mediated dissociation data (using the DH/PH domains of Tiam1) where 
applicable. (C) Graph of intrinsic and GAP-mediated single-turnover hydrolysis for 
Rac1WT, Rac1C18S, and Rac1C18D. The RhoGAP domain of p50 rhoGAP was used for the 
GTP hydrolysis measurements. The data were fit to a single exponential and standard errors 
were determined using Prism 5.0 (n = 2). (D) Bar graph of rates of nucleotide hydrolysis 
with GAP-mediated hydrolysis data (using p50 rhoGAP) where applicable. Rates of 
exchange and hydrolysis are presented in Table 1.
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Rac1 Cys18 has an altered pKa and populates the thiolate state at physiological pH. (A) 
ABD-f reactivity data for Rac1WT over a pH range of 5.5–8.5. (B) Using the initial rate of 
modification by ABD-f to Rac1WT, the initial rate of modification was plotted vs the pH to 
determine the pKa of the Cys18 thiol. The resulting curve was fit to a Boltzmann sigmoidal 
curve to determine the inflection point, indicative of the pKa, using GraphPad Prism 5.0. 
Curve fitting resulted in an estimated pKa of 7.25 for Rac1 Cys18.
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MS of Rac1WT and Rac1C18S treated with ABD-f. (A) Mass deconvoluted spectrum of 
ABD-f-treated Rac1WT. (B) Mass deconvoluted spectrum of ABD-f-treated Rac1C18S. Note: 
Rac1WT has a peak corresponding to an ABD adduct, whereas a peak at the predicted mass 
(shown by the arrow) for the corresponding ABD adduct of Rac1C18S is not observed. The 
unassigned peaks +76 and +99 Da from Rac1C18S are adducts of unknown origin. (C) ETD 
map of ABD-modified Rac1WT. Product ions generated by ETD of ABD-f-treated Rac1 are 
presented in Supplementary Fig. 3. Note that the N-terminal three residues (GHM) are not 
part of the native Rac1WT sequence. The c27+ABD, c54+ABD−H2O, c123+ABD, 
c132+ABD, and c133+ABD ions as well as the z148 ion allow for the localization of ABD to 
either Cys18 or Cys6. The absence of the ABD adduct in the Rac1C18S variant supports 
Cys18 as the site of ABD modification.
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Oxidation and mutation of Rac1 Cys18 does not perturb protein secondary structure or 
stability. (A) CD spectra (scan from 200 to 280 nm) measuring the secondary structure 
elements of Rac1WT, Rac1C18S, Rac1C18D, and Rac1S–SG. (B) Thermal denaturation of 
Rac1WT, Rac1C18S, Rac1C18D, and Rac1S–SG at 220 nm at temperatures ranging from 25 to 
95 °C. Tm values were calculated by fitting the data to a Boltzmann sigmoidal curve. Data 
are representative of three thermal melts and were fit using GraphPad Prism 5.0.
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2D NMR spectra of Rac1 and Rac1 variants. (A) 2D 1H–15N HSQC spectra overlay of 
Rac1WT (black) and Rac1C18D (magenta). Peaks that showed line broadening are shown in 
cyan and peaks with a chemical shift greater than one linewidth are in black. (B) The major 
chemical shift perturbations (broadening, where the Rac1C18D resonance linewidth is less 
than 50% of the corresponding Rac1WT resonance (shown in light pink), or shifted, where 
there was no peak detected in Rac1C18D within one linewidth of a peak in Rac1WT (shown 
in magenta) are mapped onto a ribbon diagram of GTP-bound Rac1 (pdb 1MH1). (C) 
2D 1H–15N HSQC spectra overlay of Rac1WT (black) and Rac1C18S (red). Peaks that 
showed line broadening are shown in cyan and peaks with a chemical shift greater than one 
linewidth are in black. (D) The major chemical shift perturbations (broadening, where the 
Rac1C18S resonance linewidth is less than 50% of the corresponding Rac1WT resonance 
(shown in light red), or shifted, where there was no peak detected in Rac1C18S within one 
linewidth of a peak in Rac1WT (shown in red) are mapped onto a ribbon diagram of GTP-
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bound Rac1 (pdb 1MH1). In (B) and (D), residues with chemical shifts or line broadening 
are as indicated. The unassigned and undetected residues are indicated in black, and the 
remaining residues are gray. GTP is depicted as a multicolored stick structure, and Mg2+ is 
shown as a green sphere.
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The Rac1C18D variant is hyperactivated in HEK-293T cells. Rac1WT, Rac1C18S, and 
Rac1C18D were transiently expressed in HEK-293T cells and PAK pull-down assays were 
used to assess the levels of active, GTP-bound Rac1. Active Rac1 was pulled down from 
cell lysates with PAK-PBD (p21-binding domain) coupled to agarose beads and was 
detected by immunoblotting for Rac1. A representative pull-down assay (n = 6) is shown.
Hobbs et al. Page 30














Rac1C18D enhances lamellipodia formation in Swiss 3T3 cells. To examine the effect of 
Rac1 oxidation on its ability to regulate the actin cytoskeleton, Swiss 3T3 cells were 
transfected with Rac1WT, Rac1C18S, or Rac1C18D. The actin cytoskeleton was visualized 
using phalloidin staining. (A and B) Rac1C18D induces lamellipodia formation, whereas 
Rac1C18S does not. Twenty-four hours after transfection with Myc-tagged Rac1 constructs, 
cells were fixed and stained for Myc-tag and phalloidin. Using the Myc-tag antibody to 
identify cells that express the Rac1 constructs, cells were counted (blindly with respect to 
the specific Rac1 construct expressed) for the presence or absence of lamellipodia (n = 2, 
Rac1WT, 88 cells total; Rac1C18S, 78 cells; and Rac1C18D, 92 cells). Representative images 
were collected using a Zeiss 710 microscope with a 63× oil objective and are shown in (A). 
The percentage of cells with lamellipodia was quantified (B). Statistical significance was 
determined using Student’s t test (*p = 0.05); error bars represent SEM.
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Differential modes of Rac1 and Ras activity regulation by thiol-mediated oxidants. (A) A 
linear depiction of Rac1 and residues critical for nucleotide binding. The top bar shows the 
consensus sequence for the nucleotide binding motifs with the GTPase-specific sequence 
highlighted within the box. Below, the structural depiction illustrates where the 
GxxxxGK[S/T] and [N/T]KxD motifs are located within the Rac1 structure (pdb 1MH1) and 
their proximity to the nucleotide. Cysteine 18 is approximately 3.5 Å from the α-phosphate 
(labeled PA) in Rac1 when bound to GDP or GTP. The coloring is as follows: blue, 
nitrogen; orange, phosphate; yellow, cysteine; red, oxygen; teal, carbon associated with 
Rac1; and the bound nucleotide (GMPPNP) carbons are colored magenta. (B) A linear 
depiction of Ras (pdb 3GFT) as in (A) with the structural depiction of the GxxxxGK[S/T] 
and [N/T]KxD motifs shown below. The redox-sensitive Cys118 is approximately 6.6 Å 
from the guanine ring of the bound GMPPNP nucleotide and does not make direct 
interactions with either the nucleotide or residues within Ras. In addition, the orientation of 
the Cys118 thiol is directed away from the nucleotide-binding pocket. (C) The redox-cycle 
diagram for Rac1 illustrates the effects of reactive oxygen and nitrogen species on Rac1 
nucleotide binding. Rac1 is sensitive to thiol oxidation by radical oxidants through reaction 
with Cys18, resulting in enhanced nucleotide dissociation. In addition, reaction of Rac1 with 
nonradical oxidants impairs nucleotide binding by covalent modification of Cys18. Owing to 
the proximity of Cys18 to the bound nucleotide, oxidation at this site interferes with 
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nucleotide binding, which is indicated by the oxidative modification triangle (Ox) that 
overlaps with the nucleotide, and results in increased nucleotide exchange. As oxidation 
does not affect GAP function, oxidized Rac1 can be inactivated by GAPs. Known 
nucleotide-dependent steps are labeled with diamonds with a nucleotide label and 
independent steps are shown as diamonds with no label. NO•, nitric oxide; , nitrogen 
dioxide; , superoxide; GSH, glutathione; GSSG, oxidized glutathione; H2O2, peroxide; 
GAP, GTPase-activating protein; GEF, guanine nucleotide exchange factor. (D) A redox-
cycle diagram for Ras. The redox-sensitive thiol in Ras at Cys118 does not directly interact 
with either Ras residues or the bound nucleotide; consequently, the major difference 
between Ras and Rac1 is that covalent modification of Ras Cys118 does not alter nucleotide 
binding. As such, the oxidative modification does not overlap with the bound nucleotide, as 
depicted. Labeling is the same as in (C).
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Table 1
Intrinsic and GEF-mediated GDP dissociation rates for Rac1WT, Rac1C18S, Rac1C18A, Rac1C18D, and 
Rac1S–SG.
Rac1 construct koff (s−1) intrinsic Fold increase (relative to WT) koff (s−1) with Tiam1
Rac1WT 0.71 ± 0.02 × 10−4 – 5.02 ± 0.01 × 10−4
Rac1C18S 0.81 ± 0.00 × 10−4 1.1 4.28 ± 0.03 × 10−4
Rac1C18A 7.58 ± 0.02 × 10−4 10.7 n/d
Rac1C18D 157.87 ± 1.38 × 10−4 222.4 114.73 ± 0.61 × 10−4
Rac1S–SG 167.50 ± 25.13 × 10−4 235.9 n/d
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Table 2
Intrinsic and GAP-mediated GTP hydrolysis rates for Rac1WT, Rac1C18S, and Rac1C18D.
Rac1 construct Intrinsic GTP hydrolysis (s−1) p50 rhoGAP GTP hydrolysis (s−1)
Rac1WT 0.90 ± 0.07 × 10−3 4.8 ± 0.1 × 10−3
Rac1C18S 1.50 ± 0.11 × 10−3 5.5 ± 0.3 × 10−3
Rac1C18D 0.26 ± 0.01 × 10−3 4.9 ± 0.2 × 10−3
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